Helius Med Technologies Inc Stock Price, News & Analysis

Helius Medical Technologies, Inc. (Nasdaq:HSDT) announced the appointment of Dane C. Andreeff as President and CEO and Jeffrey S. Mathiesen as CFO, effective June 14, 2021. Andreeff has served as Interim CEO since August 2020 and Mathiesen has experience in CFO roles across technology-based companies for nearly 30 years. The board expressed confidence in their leadership capabilities to guide Helius through a critical growth phase, focusing on the PoNS™ technology aimed at improving disabilities related to multiple sclerosis.

Helius Medical Technologies, a neurotech company, will participate in Noble Capital Markets’ Virtual Road Show Series on June 10, 2021. The event will feature a corporate presentation followed by a Q&A session led by Senior Research Analyst Joe Gomes. Interested parties can register for the live webcast at 1:00 p.m. Eastern Time, and a recording will be available afterwards. Helius is focused on developing non-invasive technologies that enhance neurological wellness, including the Portable Neuromodulation Stimulator (PoNS), aimed at treating gait deficits from conditions like multiple sclerosis.

Helius Medical Technologies (Nasdaq:HSDT) announced the appointment of Frederick Fantazzia as Vice President of Sales & Marketing for North America, effective June 1, 2021. Fantazzia brings 16 years of experience in the neuromodulation field, previously serving at LivaNova. He aims to develop the market for Helius’s PoNS Treatment, authorized for sale in the U.S. for multiple sclerosis patients experiencing gait deficit. This leadership change comes as the company prepares for commercialization efforts.

Helius Medical Technologies (Nasdaq:HSDT) reported Q1 2021 results showing a net loss of $3.4 million, down from $4.8 million a year prior. Revenue was $84,000 compared to $207,000 in the same quarter last year. The company received FDA marketing authorization for its Portable Neuromodulation Stimulator (PoNS™) for treating gait deficits in MS patients. Cash reserves increased to $11.4 million, up from $3.3 million at year-end 2020. Helius aims to commercialize PoNS in the U.S. in Q1 2022, while addressing reimbursement strategies following recent CMS announcements.

Helius Medical Technologies (Nasdaq:HSDT) announced participation in the Planet MicroCap Showcase from April 20-22, 2021. Management will present on April 21 at 8:30 a.m. ET. A live audio webcast of the presentation will be accessible on the investor relations website under the 'Events' section. Helius is a neurotech company dedicated to promoting neurological wellness through innovative technologies like the Portable Neuromodulation Stimulator (PoNS™), which aids in treating gait deficits due to multiple sclerosis. More details are available on their official website.

Helius Medical Technologies (NASDAQ:HSDT) announced its upcoming release of Q1 fiscal year 2021 financial results on May 17, 2021, after market close. Management will host a conference call at 5:00 PM ET to discuss the results. The Portable Neuromodulation Stimulator (PoNS™), Helius's main product, is utilized for treating gait deficits related to multiple sclerosis. The device is approved for use in the U.S. and Canada, while it remains investigational in the EU and Australia. Further details are available on Helius's investor relations website.

Helius Medical Technologies announced that its subsidiary has received FDA marketing authorization for the Portable Neuromodulation Stimulator (PoNS™). This device is the first of its kind cleared in the U.S. for treating gait deficits due to mild-to-moderate symptoms from multiple sclerosis (MS).

The PoNS device is intended for patients over 22 years, used alongside therapeutic exercises. Helius aims to commercialize this treatment in early 2022 and is pursuing Medicare reimbursement options.

Helius Medical Technologies (Nasdaq:HSDT) announced its participation in the Investor Summit Group’s Q1 Virtual Summit from March 23-25, 2021. Management will present on March 23 at 2:00 p.m. Eastern Time. A live audio webcast will be available for registered participants. Helius focuses on neurological wellness, aiming to develop non-invasive technologies that enhance the brain's healing capabilities. Its first product, the Portable Neuromodulation Stimulator (PoNS™), is authorized in Canada for treating gait deficits due to multiple sclerosis and chronic balance deficits due to mild traumatic brain injury.

Helius Medical Technologies (Nasdaq:HSDT) has announced the appointment of Sherrie Perkins to its Board of Directors, effective March 15, 2021. Perkins brings over 20 years of healthcare industry experience, particularly in neuromodulation, which is expected to enhance Helius’ market development efforts. She has previously held significant roles at LivaNova, PLC and Cyberonics, contributing to their commercial and marketing strategies. Helius focuses on neurological wellness and aims to advance therapies such as the Portable Neuromodulation Stimulator (PoNS™), currently under FDA review for classification.